Pharmafile Logo

News and Press Releases

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Eight participants achieved HBsAg loss at any time Two participants met criteria for functional cure Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. 15 November 2024 -- Oxford,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: November 15, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

Barinthus Bio Names Experienced Physician, Leon Hooftman MD, as Chief Medical Officer 

Dr Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, haematology, oncology and infectious diseases 1 May 2024 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical...

Category: BioManufacturing, Drug Discovery
Posted: May 1, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

New partnership aims to advance vaccine against MERS coronavirus

CEPI to invest up to $47m to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500 VTP-500 project with Barinthus Bio and University of Oxford, UK, uses...

Category: Clinical Trials
Posted: January 2, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD 

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level...

Category: Drug Discovery
Posted: November 27, 2023

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data  6 November 2023 -- Oxford, UK -- Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel...

Category: Drug Discovery
Posted: November 27, 2023

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF